IOM Report Faults Nation's Record of Medical Mistakes

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 9 No 1
Volume 9
Issue 1

WASHINGTON-An Institute of Medicine (IOM) committee has urged instituting a comprehensive strategy to sharply reduce medical errors that result in needless death and injury. According to an IOM report, one study put the annual number of deaths in the United States from medical mistakes at 44,000 and a second study concluded the toll reached 98,000.

WASHINGTON—An Institute of Medicine (IOM) committee has urged instituting a comprehensive strategy to sharply reduce medical errors that result in needless death and injury. According to an IOM report, one study put the annual number of deaths in the United States from medical mistakes at 44,000 and a second study concluded the toll reached 98,000.

The IOM proposes creating a National Center for Patient Safety, which would be housed in the Agency for Health Care Policy and Research and would act as a clearinghouse for objective information on patient safety. It also recommends creating a mandatory system for public reporting of medical errors, excluding certain information, such as medical mistakes that are collected solely to improve safety and quality and that have no serious consequences,

Further, the committee urged the FDA to increase its attention to public safety through efforts such as eliminating similar-sounding drug names and confusing labels and packaging that foster mistakes; and urged health care organizations to create an environment in which safety holds top priority.

Related Videos
A panel of 5 experts on colorectal cancer
A panel of 3 experts on multiple myeloma
A panel of 3 experts on multiple myeloma
A panel of 5 experts on colorectal cancer
Pegulicianine-guided breast cancer surgery may allow practices to de-escalate subsequent radiotherapy, says Barbara Smith, MD, PhD.
Adrienne Bruce Shannon, MD, discussed ways to improve treatment and surgical outcomes for patients with dMMR gastroesophageal cancer.
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Related Content